US Food and Drug Administration advisors’ general lack of confidence in risk evaluation and mitigation strategies ability to lessen safety concerns with drugs appeared to be a significant factor in the negative panel vote on 2 November against Charleston Laboratories, Inc.’s opioid combo Hydexor.
The Anesthetics and Analgesic Drugs Products Advisory Committee and Drug Safety and Risk Management Advisory Committee members who voted against...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?